# BD account plan

> BD (Becton, Dickinson and Company) is a US medical technology company with FY2025 revenues of $21.840 billion and about 72,000 associates in 61 countries.

## At a glance

Becton, Dickinson and Company (BD), headquartered in Franklin Lakes, New Jersey, develops, manufactures and sells medical supplies, devices and drug-delivery products to hospitals, clinicians, pharmacies and the pharmaceutical industry. In FY2025 (year to September 30, 2025) revenues were $21.840 billion, up 8.2%, with net income from continuing operations of $1,678 million; it employed about 72,000 associates in 61 countries. On February 9, 2026 BD completed the spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters, receiving a $4 billion cash distribution. The remaining "New BD" reports four segments: Medical Essentials, Connected Care, BioPharma Systems and Interventional.

## Business units

- **Medical Essentials** ($1,675 million in Q3 FY2026): Medication Delivery Solutions (IV catheters, vascular access, syringes and needles) and Specimen Management (BD Vacutainer blood collection). Q3 FY2026 revenue grew 4.5%, with Vacutainer share gains in the US offset by China volume-based procurement.
- **Connected Care** ($1,224 million in Q3 FY2026): Medication Management Solutions (BD Alaris infusion pumps, BD Pyxis dispensing, pharmacy automation) and Advanced Patient Monitoring, the former Edwards Lifesciences Critical Care group. Led by Bilal Muhsin; Advanced Patient Monitoring grew 10.9% in Q3 FY2026 while Alaris faced a tough prior-year comparison.
- **BioPharma Systems** ($670 million in Q3 FY2026): Prefillable syringes, safety and self-injection systems sold to pharmaceutical companies. Grew 6.6% in Q3 FY2026 on double-digit biologics growth led by GLP-1 delivery products, partly offset by lower vaccine demand.
- **Interventional** ($1,414 million in Q3 FY2026): Peripheral Intervention, Urology and Critical Care (including PureWick) and Surgery (including ChloraPrep infection prevention). Grew 6.4% in Q3 FY2026; Peter Menziuso became President of BD Interventional from June 1.

## Strategic priorities

- **Excellence Unleashed strategy**: The New BD strategy rests on three priorities: compete (gain share in the fastest-growing areas of medtech), innovate (a more focused pipeline) and deliver (safety, quality, reliable supply and cash flow).
- **Commercial investment**: Under its first Chief Revenue Officer, Mike Feld, BD put about $35 million of incremental commercial investment into targeted areas, growing the US APM and PI sales teams by 15% and deploying AI tools to sales reps.
- **Growth platforms**: BD is reallocating R&D to connected care, lower-cost care settings and chronic disease; biologic drug delivery, Advanced Patient Monitoring, PureWick and advanced tissue regeneration grew double digits in Q3 FY2026.
- **GLP-1 drug delivery**: BioPharma Systems has approximately 100 agreements signed across novel and biosimilar GLP-1 programs, and biologics are about 55% of Pharmaceutical Systems revenue.
- **BD Excellence productivity**: The manufacturing network has been cut to around 50 sites, plants deliver approximately 8% gross productivity, and a $200 million cost-out program was at a $150 million run rate in Q2 FY2026.
- **Capital allocation**: Buybacks are the top priority while net leverage of approximately 2.9x is brought toward a 2.5x target, with a 90% free cash flow conversion target over time.

## Latest results

In Q3 FY2026 (quarter ended June 30, 2026), BD's first full quarter after the Waters transaction, revenues were $4.983 billion, up 5.4% reported and 4.4% FXN; adjusted operating margin was 24.9% and adjusted EPS $3.23. Gross profit margin fell to 46.4% from 47.3% on tariffs, labor costs and El Paso charges. Nine-month operating cash flow rose to $2.104 billion and total debt fell to $16,808 million. FY2026 guidance was raised to revenue growth toward the high end of the low single-digit FXN range, an adjusted operating margin of approximately 25% and adjusted EPS of $12.62 to $12.72. FY2027 is framed as low single-digit revenue growth because of a 200 basis point Alaris headwind.

## Investments and deals

- **Waters combination**: The Biosciences and Diagnostic Solutions business was spun off and combined with Waters on February 9, 2026; BD shareholders received 39.2% of the combined company and BD used the $4 billion cash distribution for $2 billion of share repurchases and $2 billion of debt repayment.
- **Advanced Patient Monitoring acquisition**: Edwards Lifesciences' Critical Care product group was acquired on September 3, 2024 for $3.914 billion.
- **AI-enabled products**: Pyxis Pro, the first AI-enabled Pyxis, is launching, and the BD Incada AI platform will connect Alaris, Pyxis and Advanced Patient Monitoring.
- **Digital supply chain platform**: BD has begun deploying a standardized digital platform designed to run AI across its end-to-end supply chain.
- **Sterilization technology**: BD is investing in new sterilization technology to meet EPA ethylene oxide rules.

## Challenges and risks

- **FDA quality actions**: The El Paso plant making ChloraPrep and PurPrep received an FDA Warning Letter on April 30, 2026; the Alaris infusion pump consent decree remains in force.
- **Tariffs and input costs**: Tariffs cost about 110 basis points of margin in Q3 FY2026, and BD estimated that oil above $100 would mean about a $60 million to $70 million impact on COGS.
- **China, vaccines and Alaris**: China volume-based procurement and lower vaccine demand weigh on growth, and the end of Alaris remediation creates a 200 basis points headwind in FY2027.
- **Pricing and reimbursement pressure**: GPO and health-system consolidation and CMS's proposed expansion of competitive bidding pressure prices.
- **Cybersecurity**: Connected products and legacy IT increase BD's cyber exposure.

## What leadership says

> "Through BD Excellence, we've built one of the most resilient supply chains in our industry with back orders at record lows and service levels at record highs." — Thomas E. Polen, Chairman, CEO and President, Q3 fiscal 2026 earnings call, August 6, 2026

> "we now have approximately 100 agreements signed across novel and biosimilar GLP-1 programs" — Thomas E. Polen, Chairman, CEO and President, Q3 fiscal 2026 earnings call, August 6, 2026

> "We delivered a strong third quarter with revenue, adjusted operating margin and adjusted EPS all ahead of our expectations. This was our first full quarter operating as New BD." — Thomas E. Polen, Chairman, CEO and President, Q3 fiscal 2026 earnings call, August 6, 2026


## Where a supplier can help

- **Quality remediation support**: Tied to the El Paso Warning Letter: independent quality assessment, sterility assurance, contamination control and laboratory compliance providers fit BD's commitment to remediate the site.
- **Supply chain AI and data**: Tied to the digital supply chain platform investment: software, data integration and analytics vendors can support the AI platform BD is deploying across its supply chain.
- **Sales enablement tools**: Tied to the commercial investment priority: CRM, sales compensation and AI sales tools fit BD's change of rep compensation and tooling under its Chief Revenue Officer.
- **GLP-1 capacity**: Tied to the GLP-1 drug delivery priority: suppliers of components, automation and manufacturing capacity for prefillable syringes and pens can support the roughly 100 GLP-1 programs.
- **Cost and tariff mitigation**: Tied to the tariff and input-cost challenge: sourcing, resin hedging and logistics partners can help BD offset tariff and oil-linked cost increases.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report on Form 10-K for fiscal year ended September 30, 2025](https://www.sec.gov/Archives/edgar/data/10795/000001079525000099/bdx-20250930.htm)

Annual report · 2025-11-25

- BD (Becton, Dickinson and Company) is a global medical technology company selling medical supplies, devices, laboratory equipment and diagnostic products to hospitals, clinicians, labs, life science researchers, the pharmaceutical industry and the public; about 72,000 associates in 61 countries (September 30, 2025).
- FY2025 (year to September 30, 2025) revenues were $21.840 billion, up 8.2% (4.8% from the acquired Advanced Patient Monitoring unit, 3.2% volume/other, -0.3% pricing); United States $12,790 million, International $9,049 million.
- Three segments in FY2025: BD Medical ($11,456 million, segment operating income 36.1% of revenues), BD Life Sciences ($5,167 million, 31.8%) and BD Interventional ($5,217 million, 43.2%).
- Effective October 1, 2025, BD reorganized into five segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences; Life Sciences (Biosciences and Diagnostic Solutions) was to be combined with Waters Corporation in a Reverse Morris Trust, with BD shareholders owning about 39.2% of the combined company and BD receiving about $4 billion in cash.
- Strategy anchored on three pillars, "grow, simplify and empower": innovation in smart devices, robotics, analytics and AI, tuck-in acquisitions in faster-growing segments, and the BD Excellence program for productivity and margin.
- Net income from continuing operations $1,678 million, diluted EPS $5.82; operating cash flow $3.430 billion; capex $760 million; dividends $1.196 billion and about $1 billion of share repurchases; total debt $19,181 million.
- Headwinds named by the company: China volume-based procurement (VoBP), lower US government research funding, lower vaccine demand, and tariffs expected to raise FY2026 operating expense.
- Regulatory exposure: the Alaris infusion pump consent decree with the FDA, a November 2024 FDA Warning Letter on the Pyxis dispensing quality system, and ethylene oxide sterilization rules.

### [Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 (Q3 FY2026)](https://www.sec.gov/Archives/edgar/data/10795/000001079526000035/bdx-20260630.htm)

Interim report · 2026-08-06

- Q3 FY2026 (quarter ended June 30, 2026) revenues were $4.983 billion, up 5.4% reported and 4.4% FXN; United States $3,081 million (+6.9%), International $1,902 million (+3.2%, 0.6% FXN).
- First full quarter after the February 9, 2026 spin-off of the Biosciences and Diagnostic Solutions business and its combination with Waters; BD shareholders received 39.2% of the combined company and BD received a $4 billion cash distribution, used for $2 billion of share repurchases and $2 billion of debt repayment.
- Four segments now: Medical Essentials $1,675 million (+4.5%), Connected Care $1,224 million (+4.9%), BioPharma Systems $670 million (+6.6%), Interventional $1,414 million (+6.4%).
- Growth drivers: Advanced Patient Monitoring +10.9% (Acumen IQ Cuff and Sensor), double-digit prefillable biologics led by GLP-1 delivery products, PureWick, Rotarex, BD Vacutainer share gains; headwinds from China VoBP, vaccines and a tough Alaris comparison.
- New strategy "Excellence Unleashed" for "New BD", with three priorities: "compete", "innovate" and "deliver".
- Q3 net income from continuing operations $451 million, diluted EPS $1.64; nine-month operating cash flow $2.104 billion; total debt down to $16,808 million at June 30, 2026.
- On April 30, 2026 the El Paso plant (ChloraPrep, PurPrep) received an FDA Warning Letter; Q3 charges hit Interventional margins. Tariffs and labor costs cut gross margin to 46.4% from 47.3%.
- Restructuring in the first nine months included $450 million of non-cash impairments from exiting activities that no longer fit "Excellence Unleashed".

### [BD Q3 fiscal 2026 earnings call transcript](https://bullfincher.io/companies/becton-dickinson-and-company/earnings-call/fy2026-q3)

Executive talk · Thomas E. Polen, Chairman, Chief Executive Officer and President · 2026-08-06

- Tom Polen called Q3 FY2026 "our first full quarter operating as New BD": revenue $5 billion, up 4.4% FXN, adjusted operating margin 24.9%, adjusted EPS $3.23, all ahead of expectations.
- More than 90% of the portfolio grew high single digits; double-digit growth in biologic drug delivery, advanced patient monitoring, PureWick and advanced tissue regeneration. Headwinds were concentrated in "less than 10% of our portfolio": the Alaris comparison and vaccines in China.
- FY2026 guidance raised: revenue growth toward the high end of the low-single-digit FXN range, adjusted operating margin about 25%, adjusted EPS $12.62 to $12.72.
- FY2027 framed as low-single-digit revenue growth, with Alaris remediation ending to create a 200 basis point headwind, and "modest leverage" on earnings; then a return to the mid-single-digit algorithm.
- Commercial push under Chief Revenue Officer Mike Feld: about $35 million of targeted sales investment, APM US sales team up about 15%, PI US sales team up 15%; AI tools being put in sales reps' hands.
- BioPharma Systems: approximately 100 agreements across novel and biosimilar GLP-1 programs; a semaglutide launch on the Vystra pen with EMS in Brazil.
- BD Excellence delivers about 8% gross plant productivity, back orders at record lows, over 2,000 Kaizens this year; a standardized digital platform to run AI across the supply chain is being deployed.
- Capital allocation: about $2.3 billion of buybacks year to date, net leverage about 2.9x (target 2.5x), 90% free cash flow conversion target over time; an Investor Day is planned.

### [BD Q2 fiscal 2026 earnings call transcript](https://bullfincher.io/companies/becton-dickinson-and-company/earnings-call/fy2026-q2)

Executive talk · Thomas E. Polen, Chairman, Chief Executive Officer and President · 2026-05-07

- On the May 7, 2026 call, Tom Polen named Vitor Roque CFO (interim CFO "since last fall", 25 years at BD) and said the Waters transaction closed "ahead of schedule".
- Q2 FY2026 revenue was $4.7 billion, up 2.6%; adjusted operating margin 24.2%, adjusted EPS $2.90; FY2026 adjusted EPS guidance raised to $12.52 to $12.72.
- Growth platforms (biologic drug delivery, Advanced Patient Monitoring, PureWick, Advanced Tissue Regeneration) grew double digits; Alaris, vaccines and China, under 10% of revenue, weighed.
- BD Excellence: manufacturing network cut roughly in half to about 50 sites, about 8% productivity, $150 million run rate of a $200 million cost-out program; applied to R&D, cutting time to launch by over 10 months on five programs.
- El Paso FDA Warning Letter: ChloraPrep and PurPrep placed on a voluntary US ship hold for about 3 weeks of extra release testing; "no patient safety signals".
- Capital allocation now puts share buybacks first, as BD views its stock as "substantially undervalued", ahead of focused tuck-in M&A; $2 billion repurchased in the quarter and $2.1 billion of debt retired.
- Connected Care: Pyxis Pro, "the first AI-enabled Pyxis", with 75% of wins from competitive conversions; the BD Incada AI platform will connect Alaris, Pyxis and APM.
- GLP-1: two new next-generation GLP-1 deals with large pharma, over 80 biosimilar GLP-1 deals; biologics now about 55% of Pharmaceutical Systems revenue.

## Questions about BD

### What does BD do?

BD develops, manufactures and sells medical supplies, devices and drug-delivery systems, including IV catheters, BD Vacutainer blood collection, BD Alaris infusion pumps, BD Pyxis dispensing, prefillable syringes and interventional products, to hospitals, pharmacies and pharmaceutical companies.

### What is BD's revenue?

FY2025 revenues were $21.840 billion, up 8.2%. In Q3 FY2026, after the Waters transaction, quarterly revenues were $4.983 billion.

### How many employees does BD have?

BD employed approximately 72,000 associates in 61 countries as of September 30, 2025.

### Who leads BD?

Thomas E. Polen is Chairman, Chief Executive Officer and President; Vitor Roque is Executive Vice President and CFO.

### What is BD's strategy?

Under "Excellence Unleashed", BD aims to compete, innovate and deliver: gain share in fast-growing medtech areas, focus its pipeline on connected care and chronic disease, and use BD Excellence for supply and margin.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
